ACADIA Pharmaceuticals (ACAD) AI Stock Analysis

Compare

2,435 Followers

Top Page

ACADIA Pharmaceuticals

(NASDAQ:ACAD)

Select Model

Outperform 75 (OpenAI - 4o)

Rating:75Outperform

Price Target:

$28.00

▲(14.01% Upside)

Action:ReiteratedDate:11/30/25

ACADIA Pharmaceuticals is well-positioned with strong financial performance, robust technical indicators, and strategic growth initiatives. The company's reasonable valuation and positive earnings call sentiment further support its potential for future growth. However, operational efficiency improvements and market penetration challenges for DAYBUE remain areas to watch.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and successful product sales, supporting long-term financial stability and expansion.

Pipeline Advancements

Ongoing pipeline advancements demonstrate ACADIA's commitment to innovation and potential for future revenue streams from new treatments.

Cash Position

A strong cash position provides financial flexibility for strategic investments and R&D, supporting long-term growth and stability.

Negative Factors

DAYBUE Market Penetration Challenges

Low market penetration for DAYBUE highlights challenges in gaining market share, which could impact revenue growth and long-term success.

R&D Expense Increase

Rising R&D expenses may strain profitability if not matched by revenue growth, affecting financial performance and investment capacity.

Disappointment in Canada

Challenges in securing reimbursement can limit market access and revenue potential, impacting international expansion efforts.

ACADIA Pharmaceuticals (ACAD) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$4.19B

Dividend YieldN/A

Average Volume (3M)1.38M

Price to Earnings (P/E)10.7

Beta (1Y)1.09

Revenue Growth12.69%

EPS Growth100.80%

CountryUS

Employees653

SectorHealthcare

Sector Strength45

IndustryBiotechnology

Share Statistics

EPS (TTM)1.60

Shares Outstanding169,181,820

10 Day Avg. Volume1,549,073

30 Day Avg. Volume1,382,274

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)4.15

Price to Sales (P/S)3.17

P/FCF Ratio19.34

Enterprise Value/Market Cap0.81

Enterprise Value/Revenue3.22

Enterprise Value/Gross Profit3.51

Enterprise Value/Ebitda28.78

Forecast

1Y Price Target

$32.57

Price Target Upside32.61% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering15

EPS Forecast (FY)0.49

Revenue Forecast (FY)$1.20B

ACADIA Pharmaceuticals Business Overview & Revenue Model

Company DescriptionACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

How the Company Makes MoneyACADIA Pharmaceuticals generates revenue primarily through the sales of its flagship product, NUPLAZID, which is marketed in the United States and other markets where it has received regulatory approval. The company employs a direct-to-consumer and direct-to-healthcare provider sales strategy, targeting neurologists and psychiatrists involved in the treatment of Parkinson's disease and related disorders. Additionally, ACADIA may engage in collaborations and partnerships with other pharmaceutical companies or research institutions to co-develop new therapies, which can provide milestone payments and royalties on future product sales. The company's revenue model is further supported by ongoing clinical trials and research that may lead to the expansion of its product portfolio with new indications or drugs, thus creating additional revenue streams.

ACADIA Pharmaceuticals Key Performance Indicators (KPIs)

Any

Revenue by Product

Revenue by Product
Shows earnings from individual products, highlighting which offerings drive growth and which may need strategic adjustments. This helps assess product portfolio strength and market positioning.

Chart InsightsNUPLAZID remains the revenue engine with steady sequential growth, while DAYBUE has moved from launch to a meaningful commercial contributor — recent sales milestones validate the commercialization ramp and underpin raised guidance. That diversification de‑risks ACADIA’s revenue profile and funds heavier R&D and sales investment (including a planned 30% field expansion), but DAYBUE’s sub‑50% U.S. penetration and reimbursement setbacks abroad are the primary execution risks that could cap upside and pressure margins despite a strong cash position.

Data provided by:

The Fly

ACADIA Pharmaceuticals Earnings Call Summary

Earnings Call Date:Feb 25, 2026

(Q4-2025)

% Change Since: |

Next Earnings Date:May 13, 2026

Earnings Call Sentiment Positive

The call conveyed strong commercial momentum and clear growth drivers: record adjusted revenue (> $1 billion), double-digit growth for both NUPLAZID and DAYBUE, an approved new DAYBUE formulation (STIX) with early traction, meaningful pipeline catalysts (remlifanserin Phase II readout in Aug–Oct 2026 and multiple planned study initiations), and a solid cash position. Offsetting these positives were industry- and company-specific risks: a negative CHMP trend vote for trofinetide in the EU creating regulatory uncertainty, a nonrecurring $20M IRA-related net sales adjustment plus cash outflows from IRA invoices, and a notable step-up in SG&A that will pressure near-term margins. On balance, the highlights — notably strong top-line growth, product launches, pipeline catalysts, and healthy cash — outweigh the lowlights, which are largely regulatory and timing risks.

Q4-2025 Updates

Positive Updates

Record Annual Revenue Exceeding $1 Billion

Adjusted 2025 total revenues reached $1.08 billion, a 14% increase year-over-year; Q4 adjusted total revenues were $298 million, up 16% YoY — first time company annual revenues exceeded $1 billion.

NUPLAZID Strong Sales and Volume Growth

Adjusted NUPLAZID net sales were $189 million in Q4 (up 17% YoY) and $692 million for the full year (up 15% YoY); volume growth of 13% in Q4 and 9% for the full year; new prescriptions grew 18% YoY in Q4.

NUPLAZID 2026 Guidance and Long-Term Outlook

2026 NUPLAZID net sales guidance of $760–$790 million (10%–14% growth vs. 2025 adjusted); management reiterates path to approximately $1 billion annual sales by 2028.

DAYBUE Growth and New Formulation Launch

DAYBUE net product sales were $110 million in Q4 (up 13% YoY) and $391 million for 2025 (up 12% YoY); Q4 volume up 12%. FDA-approved DAYBUE STIX (powder for oral solution) approved Dec 2025, early commercial interest reported; management estimates >400 incremental patients addressable over 2–3 years.

International Expansion for DAYBUE

Named patient supply programs expanding ex-U.S.; DAYBUE liquid approved in three markets including recent approval in Israel, supporting global access outside EU approval pathway.

R&D Pipeline Momentum and Key Catalysts

Four unique molecules with combined peak sales potential of ~$11 billion; remlifanserin ~ $4 billion potential across ADP and LBDP; Phase II readout for remlifanserin expected Aug–Oct 2026; Phase III trofinetide study initiated in Japan with readout expected Q4 2026–Q1 2027; plan to initiate 5 additional Phase II/III studies by end of 2027; ACP-271 first-in-human expected before end of Q1 2026.

Solid Financial Position and One-Time Tax Benefit

Cash balance of $820 million at year-end 2025 and a one-time noncash income tax benefit of approximately $250 million related to releasing the valuation allowance on deferred tax assets.

2026 Financial Guidance

Company guides to total revenues of $1.22–$1.28 billion for fiscal 2026; DAYBUE guidance of $460–$490 million (18%–25% growth vs. 2025) driven by STIX and named patient supply; R&D expense guidance $385–$410 million; SG&A guidance $660–$700 million.

Commercial Execution and Field Expansion

NUPLAZID customer-facing team expanded ~30% (deployed by January 2026) increasing prescriber target universe from ~7,000 to ~11,000 writers; DAYBUE community expansion showed 76% of new prescriptions from community-based physicians in Q4; DAYBUE shipments reached a record 1,070 patients in Q4.

Negative Updates

Negative CHMP Trend Vote for Trofinetide (DAYBUE) in EU

Following an oral explanation to CHMP, management was informed of a negative trend vote and expects a negative final opinion; company will request reexamination (~120 days), creating uncertainty and excluded EU commercial sales from 2026 guidance; EU represents <15% of the firm's 2028 DAYBUE projection but adds regulatory risk.

Inflation Reduction Act (IRA) Invoices and Nonrecurring Adjustment

Received CMS IRA invoices indicating higher Medicare volume than previously accrued, prompting a change in estimate that produced a nonrecurring $20 million reduction in reported net sales (apportioned across applicable years); Q4 GAAP NUPLAZID net product sales $174M vs. adjusted $189M.

Cash Outflow Related to IRA Payments

Company paid invoices during the year (first two years total payment of $108 million) with a net cash flow impact for the year of approximately $30 million, indicating tangible near-term cash effects from IRA invoicing.

Higher SG&A and Short-Term OpEx Pressure

Q4 SG&A rose to $156 million from $130 million YoY driven by marketing and field expansions; 2026 SG&A guidance of $660–$700 million reflects a material step-up in operating spend to support launches and field expansion, which may compress near-term margins.

Gross-to-Net Pressure on NUPLAZID

NUPLAZID gross-to-net was 29.4% reported in Q4 (23.6% adjusted) and 25.9% reported for the full year (24.6% adjusted), indicating substantial deductions that reduce realized net sales.

Regulatory and Clinical Risks for Pipeline Programs

Remlifanserin Phase II readout (Aug–Oct 2026) is a material near-term catalyst but faces typical clinical risks (placebo effect, powering uncertainties); CHMP reexamination and global regulatory expectations add uncertainty to commercialization timelines.

Dependence on Successful Trial Readouts and Execution

Growth trajectory and long-term targets (e.g., NUPLAZID and remlifanserin achieving multi-hundred-million to billion-dollar peaks) depend on successful Phase II/III readouts and efficient trial execution; competition (e.g., Cobenfy) and operational irregularities in the industry are noted as potential risks.

Company Guidance

The company guided 2026 adjusted total revenues of $1.22–$1.28 billion, driven by NUPLAZID net sales of $760–$790 million (10–14% growth vs. 2025 adjusted; midpoint ~$775M, volume-driven) with a gross‑to‑net of 22–24%, and DAYBUE global net sales of $460–$490 million (18–25% growth vs. 2025; guidance excludes potential incremental EU approval sales but includes named‑patient programs) with a gross‑to‑net of 22–24%; 2026 expense guidance was R&D $385–$410 million and SG&A $660–$700 million, cash at year‑end 2025 was $820 million, and management reiterated 2028 targets of ~$1 billion for NUPLAZID and $700 million for DAYBUE (EU <15% of DAYBUE 2028 sales), noted a company CAGR to 2028 of ~16%, projected operating margins in the mid‑teens with no R&D attrition (low‑20s with typical attrition), and cited key 2025 comparators used to set guidance: adjusted 2025 revenue $1.08 billion (+14%), adjusted NUPLAZID FY $692M (+15%) and Q4 $189M (+17%, volume +13% Q4 / +9% FY), Q4 DAYBUE $110M (+13%, volume +12%), reported vs. adjusted NUPLAZID gross‑to‑net Q4 29.4%/23.6% and FY 25.9%/24.6%, DAYBUE gross‑to‑net Q4 19.5% and FY 22.3%, and a one‑time $20 million nonrecurring net‑sales reduction from an IRA accrual change.

ACADIA Pharmaceuticals Financial Statement Overview

Summary

ACADIA Pharmaceuticals shows strong profitability with a consistent gross profit margin over 91% and positive net profit margin. Revenue growth is steady, and the balance sheet reflects low leverage. However, there is room for operational efficiency improvements and better cash flow conversion.

Income Statement

Positive

ACADIA Pharmaceuticals has shown a strong gross profit margin of over 91% consistently, indicating efficient cost management. The net profit margin has improved significantly, turning positive in the TTM period, reflecting enhanced profitability. Revenue growth is steady, with a notable increase in the TTM period. However, EBIT and EBITDA margins are relatively low, suggesting room for operational efficiency improvements.

Balance Sheet

Positive

The company maintains a low debt-to-equity ratio, indicating conservative leverage and financial stability. Return on equity has turned positive, showcasing improved profitability and shareholder returns. The equity ratio suggests a solid capital structure, though there is potential to optimize asset utilization further.

Cash Flow

Positive

Operating and free cash flows have improved, with positive growth rates indicating better cash generation capabilities. The operating cash flow to net income ratio is below 1, suggesting that not all net income is translating into cash flow, which could be a concern. However, the free cash flow to net income ratio is close to 1, indicating efficient cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.05B	957.80M	726.44M	517.24M	484.14M	441.75M
Gross Profit	962.54M	875.96M	680.71M	507.07M	465.00M	421.20M
EBITDA	117.30M	100.16M	-67.83M	-221.57M	-167.09M	-283.65M
Net Income	261.17M	226.45M	-61.29M	-215.97M	-167.87M	-281.58M
Balance Sheet
Total Assets	1.33B	1.19B	748.96M	587.81M	700.12M	782.62M
Cash, Cash Equivalents and Short-Term Investments	847.02M	755.99M	438.87M	416.82M	520.71M	631.96M
Total Debt	54.81M	51.99M	57.20M	62.00M	64.43M	49.55M
Total Liabilities	413.50M	454.96M	317.20M	187.40M	159.23M	155.61M
Stockholders Equity	917.27M	732.79M	431.75M	400.41M	540.89M	627.01M
Cash Flow
Free Cash Flow	197.81M	157.20M	-23.35M	-114.03M	-126.78M	-143.75M
Operating Cash Flow	198.95M	157.72M	16.70M	-114.03M	-125.66M	-136.17M
Investing Cash Flow	-124.55M	-30.54M	32.00M	73.24M	-71.10M	192.51M
Financing Cash Flow	29.19M	6.84M	25.13M	8.20M	18.16M	81.00M

ACADIA Pharmaceuticals Technical Analysis

Technical Analysis Sentiment

Positive

Last Price24.56

Price Trends

50DMA

25.63

Negative

100DMA

24.47

Positive

200DMA

23.69

Positive

Market Momentum

MACD

-0.26

Negative

RSI

50.46

Neutral

STOCH

84.92

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACAD, the sentiment is Positive. The current price of 24.56 is above the 20-day moving average (MA) of 23.86, below the 50-day MA of 25.63, and above the 200-day MA of 23.69, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 50.46 is Neutral, neither overbought nor oversold. The STOCH value of 84.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACAD.

ACADIA Pharmaceuticals Risk Analysis

ACADIA Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. ACADIA Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

ACADIA Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	81 Outperform	$8.06B	40.27	18.91%	―	54.51%	275.94%
ACAD	75 Outperform	$4.19B	10.73	39.89%	―	12.69%	100.80%
ARWR	69 Neutral	$8.86B	41.13	65.14%	―	23258.15%	99.12%
PTCT	65 Neutral	$5.64B	8.81	―	―	97.54%	―
ACLX	64 Neutral	$6.65B	-28.06	-47.18%	―	-76.96%	-425.41%
MLTX	55 Neutral	$1.24B	-4.97	-60.51%	―	―	-157.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

ACAD

ACADIA Pharmaceuticals

24.56

6.40

35.24%

ARWR

Arrowhead Pharmaceuticals

63.27

45.56

257.26%

PTCT

PTC Therapeutics

68.19

15.32

28.98%

KRYS

Krystal Biotech

275.64

103.81

60.41%

MLTX

MoonLake Immunotherapeutics

17.51

-22.20

-55.91%

ACLX

Arcellx Inc

113.79

51.16

81.69%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 30, 2025